{"id":135925,"date":"2024-06-07T08:43:11","date_gmt":"2024-06-07T12:43:11","guid":{"rendered":"https:\/\/ccs.ca\/?post_type=news&p=135925"},"modified":"2024-06-07T08:43:14","modified_gmt":"2024-06-07T12:43:14","slug":"canadian-cardiovascular-society-awarded-1-4m-to-continue-important-national-study-of-covid-19-and-mrna-vaccines","status":"publish","type":"news","link":"https:\/\/ccs.ca\/news\/canadian-cardiovascular-society-awarded-1-4m-to-continue-important-national-study-of-covid-19-and-mrna-vaccines\/","title":{"rendered":"Canadian Cardiovascular Society Awarded $1.4M to Continue Important National Study of COVID-19 and mRNA Vaccines"},"content":{"rendered":"\n

Funding will support continued recruitment and follow-up of patients who experienced myocarditis and\/or pericarditis after mRNA vaccine or COVID-19 infection<\/em><\/p>\n\n\n\n

OTTAWA \u2014\u00a0<\/strong>New funding from the Public Health Agency of Canada (PHAC) will enable top Canadian cardiology researchers and clinicians to continue a large multi-centre and multi-year study on the impact of COVID-19 and mRNA vaccines.

MYCOVACC (Canadian Cardiovascular Society National Active Surveillance Study of\u00a0MY<\/strong>ocarditis and\/or Pericarditis following mRNA\u00a0CO<\/strong>VID-19\u00a0VACC<\/strong>ination) will receive an additional $1.4 million in funding for its third year, bringing the total investment to $5 million.\u00a0

Research began during the global pandemic in 2022 amid reports of rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining surrounding the heart muscle) following mRNA vaccines and COVID-19 infection.\u00a0At the time, the Canadian Cardiovascular Society (CCS)\u00a0mobilized its network of 2,300 members, as well as cardiac care centres and partner organizations across the country, to study the issue in adults and children.\u00a0

Funding announced today will support:<\/p>\n\n\n\n